TripletDGC links disease genes→cell types→diseases via eQTL-scRNA integration, exposing sparse but critical cell drivers and potential comorbidity ...
Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. The data ...
One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...
Share on Pinterest Are researchers getting closer to functionally curing type 1 diabetes? Image credit: Costfoto/NurPhoto via Getty Images. A woman has undergone a stem-cell therapy made from her own ...
Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...
Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback